Summary Vascular endothelial growth factor (VEGF) may affect the phenotype of cancer cells, such as growth velocity and metastatic potential, due to its probable multifunctional property including a mitogenic activity for vascular endothelial cells. The present study was designed to investigate the association of VEGF mRNA expression with progression and metastasis of human colorectal cancer. The level of VEGF mRNA expression was quantified by Northem blot hybridization in tumorous and non-tumorous tissues obtained from 60 primary colorectal cancer patients. The ratio of the former to the latter was defined as the VEGF T/N ratio, and the prognostic significance of this ratio, following surgery, in addition to the relationship to progression and metastatic potential, was evaluated. The value of the VEGF T/N ratio was significantly correlated with the depth of tumour infiltration (P = 0.046), the incidence of liver metastasis (P < 0.0001) and lymph node metastasis (P = 0.036). Patient prognosis was estimated by the Kaplan-Meier method and the log-rank test. When the VEGF T/N ratio was higher than 4.8 for which the X2 value of the log-rank test was maximal, the tumour was defined as showing overexpression of VEGF mRNA.
Vascular endothelial erowth factor (VEGF) w-as discovered in 1983. and first called xascular permeability factor (VPF) (Senger et al. 1983) . In 1989. a growth factor specific for Xascular endothelial cells was purified form the media conditioned by box ine pituitarv follicular stellate cells. and this factor was named VEGF (Ferrara et al. 1989) .
Recent studies hax e demonstrated that VEGF is strongiv expressed in several human solid tumours. and its expression is correlated xith the density of microxessels in tumours of the kidney (Takahashi et al. 1994) . breast (Toi et al. 1994 ). brain (Berkman et al. 1993 : Samoto et al. 1995 . colon (Takahashi et al. 1995 : Takahashi et al. 1997 . stomach (Maeda et al. 1996) . lung (Mattern et al. 1996) . oesophagus (Inoue et al. 1997 ) and liver (Mise et al. 1996) . Concerning VEGF expression in colorectal cancer tissues. Broxn et al (1993) first described that the malihnant epithelial cells strongly expressed VEGF mRNA in contrast to normal epithelium by in situ hbnridization. and that tumour cells stained stronalv for VEGF protein by immunohistochemistrx (Brown et al. 1993) . Furthermore. experimental studies haxe shoxxn that tumours wxith high expression of VEGF grewx rapidls (Ferrara et al. 1993 : Kondo et al. 1993 ) and exhibited metastatic abilitx (Asano et al. 1995 : Warren et al. 1995 . However. verv fex clinical in estigations have been reported regarding the correlation bet-een VEGF and the progression of colorectal cancer. Takahashi et al (1995) showed that VEGF expression at protein lex el detected bv immunohistochemistry x as correlated with xvessel count in the tumour and metastasis. and mav be useful for predicting distant recurrence in patients with node-negatixe colon cancer (Takahashi et al. 1997) . Howexer. thev did not make clear the correlation betxween VEGF expression and hepatic or lNmph node metastasis.
In the present study. w e directed our attention to the relationship among VEGF mRNA expression w-ith Northern blot analysis. clinicopathological xariables. including hepatic and lymph node metastasis. and survival with prospective study.
Northern blot analysis is thought to provide a more objectixe quantification than immunohistochemical study and w-e preferred this method to immunohistochemistrv. Moreoxer. considerinn, that biolooical activities of VEGF are not merely induction of anaiogenesis (Gabrilovich et al. 1996 : Tsurumi et al. 1997 : van der Zee et al. 1997 we focused on VEGF mRNA expression itself wxithout study ina the correlation with number of v-essels in the tumour.
Exvidence w ill be presented indicatina that VEGF mRNA expression plays a predictive role in the prognosis and the hepatic and lymph node metastasis of colorectal cancer patients. . _w-~~~~~~~~~~S26 rpmRNA To determine the optimal cut-off point of the VEGF T/N ratio. an analytical method prexiouslv reported was used (Miller and Siegmund. 1982) . When the VEGF T/N ratio xas higher than 4.8. for which the X xvalue of the log-rank test wxas maximal. we defined such a tumour as showing ox erexpression of VEGF mRNA. JMP-3.1.5 softwxare (SAS Institute. Can'. NC. USA) and Stat View-J 4.5 software (Abacus Concepts. Berkelev. CA. USA) were used for the analyses. and P < 0.05 A-as considered to be statistically sirnificant. 
Patient prognosis
During the follow-up term. 21 patients died as a result of recurrence (10 of 11 patients with overexpression of VEGF mRNA. and 11 of 45 patients without overexpression of VEGF mRNA). To define the significance of the VEGF T/N ratio as an independent prognostic marker, four variables (the VEGF T/N ratio, tumour size, depth of tumour infiltration and tumour differentiation), which reflect malignant potential of the primary tumour, were selected. and both univariate and multivariate analysis were performed using Cox's regression model (Table 2) . According to univariate analysis, overexpression of VEGF mRNA (P < 0.0001), depth of tumour infiltration (P = 0.013) and tumour differentiation (P = 0.043) were associated with poor overall survival of colorectal cancer patients. Multivariate analysis demonstrated that the overall estimated hazard ratio for death in patients with overexpression of VEGF mRNA was 1.94 (95% confidence interval, 1.23-3.06, P = 0.005). and that the VEGF T/N ratio was the most significant prognostic marker for overall survival among these variables. Survival rates of these 56 patients with or without overexpression of VEGF mRNA are shown in Figure 2 . One-, 2-and 3-year survival rates of the patients without overexpression of VEGF mRNA were 86.7. 77.4 and 74.9% respectively, whereas 1-and 2-year survival rates of the patients with overexpression of VEGF mRNA were 54.5 and 18.2%
respectively. The patients with overexpression of VEGF mRNA demonstrated poorer survival than the patients without overexpression of VEGF mRNA by both the log-rank test (P < 0.001) and the Wllcoxon test (P = 0.0002).
DISCUSSION
Multistep carcinogenesis in colon cancer is a well-recognized mechanism that was originally proposed by Vogelstein et al (1988) . However, no clear explanation has been provided at the molecular level of invasion or metastasis following carcinogenesis. Recent investigations have suggested possible participants in the metastatic potential of cancer cells such as adhesion molecules, proteinases, angiogenic factors, etc. In the present study, we directed our attention to an angiogenic molecule. VEGF. which is the most potent mitogen specific for vascular endothelial cells. mainly because angiogenesis seems to be a prerequisite for the growth of solid tumours. Many reports have shown a correlation between neovascularization in tumours and VEGF expression. indicating the important role of VEGF in tumour angiogenesis. However, VEGF has some different functions from mitogenic activity for vascular endothelial cells (Gabrilovich et al, 1996; Tsurumi et al, 1997 : van der Zee et al. 1997 ). and we thus attempted to evaluate the association of VEGF mRNA expression with the progression of colorectal cancer apart from its angiogenic role. The reason we chose the VEGF mRNA as a determinant, but not VEGF protein. was that Northern blot analysis is more objective as a quantitative measurement than the immunohistochemical method.
The results here demonstrated that the expression of VEGF mRNA was highest in the Dukes' D class, representing those tumours with either extended lymph node metastasis, liver metastasis or peritoneal dissemination. Actually, higher expression of VEGF mRNA in the primary tumours was observed in the presence of lymph node involvement or hepatic metastasis than in those without. Moreover, VEGF gene expression in the tumour tended to be augmented as the severity of cancer involvement in the vasculolymphatic system increased (data not shown).
VEGF may play a broader role in the biological and pathological characteristics of cancer than was previously thought. The rationale for the participation of VEGF in the metastatic potential of tumours may be as follows. First, an increase in the microvascular density of tumours may increase the probability that cancer cells break loose into the circulatory system. The development of vascular networks possibly leads to increases in lymphocapillary anastomoses, which may contribute to the invasion of cancer cells into the vasculolymphatic system. Second. the ability of tumours to grow at a metastatic site is dependent at least in part on neovascularization (Folkman et al. 1990 ). Third. VEGF may facilitate invasive potential by degrading the extracellular matrix through plasminogen activation. Namely. VEGF is thought to induce plasminogen activator (PA) in vascular endothelial cells, which leads to the conversion of plasminogen to plasmin (Pepper et al, 1991 : Mandriota et al. 1995 . Plasmin in tum, activates a latent form of the matrix metalloproteinases (MMPs) (Keski et al, 1992 : Montgomery et al, 1993 Baricos et al, 1995) . Finally, VEGF inhibits the functional maturation of dendritic cells, which are the most effective antigen-presenting cells in the induction of primary immune responses (Gabrilovich et al, 1996) , possibly leading to an immunosuppressive state. With regard to regulation of VEGF production. hypoxia, glucose deficiency and certain cytokines are supposed to up-regulate VEGF expression (Pertovaara et al, 1994; Li et al, 1995 : Shweiki et al, 1995 Cohen et al, 1996) . Recently, Kieser et al (1994) reported that mutant p53 up-regulated VEGF production through the activation of protein kinase C. However, we did not obtain a clear correlation between immunohistochemically detected mutation of p53 and mRNA expression of VEGF (the VEGF T/N ratio in p53 mutation negative samples; 4.32 ± 5.64 vs p53 mutation-positive samples; 3.83 ± 4.10), although direct sequencing of the p53 gene was not performed. Furthermore, no significant correlation was seen between the expression of interleukin 1, interleukin 6, transforming growth factor m and VEGF (data not shown). Hereafter, more detailed studies are needed to clarify the regulatory mechanism of VEGF expression in colorectal cancer.
In the present study, we examined whether the levels of VEGF mRNA expression in the primary site of colorectal cancer facilitate prediction of patient prognosis or not. When the cut-off point of the VEGF T/N ratio ranged from 2.8 to 12.0, the difference between survivors and non-survivors was statistically significant. To determine the optimal cut-off point of the VEGF T/N ratio, the analytical method introduced by Miller and Siegmund (1982) was used. Consequently. 4.8 was detenmined to be the optimal cut-off point of the VEGF T/N ratio, and a tumour with this ratio exceeding 4.8 was defined as demonstrating overexpression of VEGF mRNA.
In the multivariate analysis, we selected three variables, depth of tumour infiltration, tumour size and tumour differentiation, other than the VEGF T/N ratio, because all of these variables have been designated as putative prognostic factors based on conventional histopathological studies of primary tumours. This analysis revealed that expression intensity of VEGF mRNA was the most reliable prognostic indicator among these factors.
Thus, we found that VEGF was associated with the progression, and was presumably a significant participant in the metastatic potential of colorectal cancer. These results suggest that the determination of VEGF mRNA expression in colorectal cancer makes it possible to predict post-operative patient prognosis and that the VEGF T/N ratio can be used as an independent prognostic marker in colorectal cancer patients.
